尼达尼布的临床药代动力学与药效学
本文综述尼达尼布在健康志愿者和晚期癌症患者中的药代动力学与药效学特征;尼达尼布口服后约2-4小时达峰,暴露随剂量成比例增加,经酯水解和葡萄糖醛酸化后主要经粪便排泄,性别和肾功能不影响药代动力学,中重度肝损伤不建议使用,药物相互作用风险低。
要点
- 尼达尼布50-450mg每日一次和150-300mg每日两次范围内暴露成比例增加,终末半衰期约10-15小时。
- 性别和肾功能不影响尼达尼布药代动力学,无需根据性别或肾功能调整剂量。
- 中重度肝损伤患者不推荐使用尼达尼布,轻度肝损伤患者需密切监测并调整剂量。
核心结论
- 尼达尼布具有时间非依赖性药代动力学特征,暴露随剂量成比例增加,性别和肾功能不影响其药代动力学。
- 中重度肝损伤患者不推荐使用尼达尼布,轻度肝损伤患者需密切监测并调整剂量。
- 尼达尼布药物相互作用风险低,尤其与经细胞色素P450酶代谢的药物,但与强效P-糖蛋白抑制剂或诱导剂合用可影响其药代动力学。
研究设计与样本
- 综述总结了在健康志愿者和晚期癌症患者中进行的药代动力学和药效学研究。
主要发现
- 口服尼达尼布后约2-4小时达最大血浆浓度,此后至少呈双指数下降。
- 在研究的剂量范围50-450mg每日一次和150-300mg每日两次内,尼达尼布暴露增加呈剂量比例。
- 尼达尼布通过水解酯裂解代谢,形成游离酸部分随后葡萄糖醛酸化并随粪便排泄,少于1%的药物相关放射性在尿液中消除。
- 终末消除半衰期约为10-15小时,每日两次重复给药后蓄积可忽略不计。
- 性别和肾功能对尼达尼布药代动力学无影响,种族、低体重、高龄和吸烟的影响在患者间暴露变异范围内,无需调整剂量。
关键数值与推荐
- 尼达尼布在研究剂量200mg每日两次下无致心律失常潜力。
临床怎么用
- 尼达尼布用于特发性肺纤维化和晚期非小细胞肺癌腺癌组织学患者的治疗。
- 轻度肝损伤患者使用尼达尼布需密切监测并相应调整剂量,中重度肝损伤患者不推荐使用。
- 与强效P-糖蛋白抑制剂或诱导剂合用时需注意可能影响尼达尼布的药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF). Studies in healthy volunteers and in patients with advanced cancer have shown that nintedanib has time-independent pharmacokinetic characteristics. Maximum plasma concentrations of nintedanib are reached approximately 2-4 h after oral administration and thereafter decline at least bi-exponentially. Over the investigated dose range of 50-450 mg once daily and 150-300 mg twice daily, nintedanib exposure increases are dose proportional. Nintedanib is metabolised via hydrolytic ester cleavage, resulting in the formation of the free acid moiety that is subsequently glucuronidated and excreted in the faeces. Less than 1% of drug-related radioactivity is eliminated in urine. The terminal elimination half-life of nintedanib is about 10-15 h. Accumulation after repeated twice-daily dosing is negligible. Sex and renal function have no influence on nintedanib pharmacokinetics, while effects of ethnicity, low body weight, older age and smoking are within the inter-patient variability range of nintedanib exposure and no dose adjustments are required. Administration of nintedanib in patients with moderate or severe hepatic impairment is not recommended, and patients with mild hepatic impairment should be monitored closely and the dose adjusted accordingly. Nintedanib has a low potential for drug-drug interactions, especially with drugs metabolised by cytochrome P450 enzymes. Concomitant treatment with potent inhibitors or inducers of the P-glycoprotein transporter can affect the pharmacokinetics of nintedanib. At an investigated dose of 200 mg twice daily, nintedanib does not have proarrhythmic potential.
引用
- Wind S, Schmid U, Freiwald M, et al. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019. PMID: 31016670. doi:10.1007/s40262-019-00766-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。